FDA Approves Topical JAK Inhibitor For Vitiligo
ADC评论
July 20, 2022
On July 19, Incyte announced that the FDA approved ruxolitinib cream 1.5% for the topical treatment of non-segmental vitiligo in adults and children over 12
